Aging has long been treated as an inevitable slide toward slower thinking, patchier memory, and a brain quietly simmering in its own inflammatory chemistry. A new study published in npj Parkinson’s Disease suggests that this trajectory may be far more negotiable than previously assumed. The research reports that polysaccharides extracted from Ganoderma lucidum, the reishi mushroom revered for centuries in East Asian traditional medicine, can ameliorate cognitive decline and neuroinflammation associated with aging. The mechanism at the heart of the finding is striking: the compounds appear to work not by acting on the brain directly, but by reshaping the gut microbiome in a way that calms inflammatory signaling in the nervous system.
The study’s central discovery centers on a tripartite axis linking a specific gut bacterium, a short-chain fatty acid, and an intracellular inflammatory machine. According to the findings, Ganoderma lucidum polysaccharides boost populations of Blautia coccoides, a commensal bacterium known for its capacity to produce butyrate. Butyrate, in turn, suppresses the activation of the NLRP3 inflammasome, a multiprotein complex that acts as a molecular alarm bell inside immune cells. When NLRP3 is restrained, the cascade that ultimately releases interleukin-1 beta and other potent inflammatory messengers is dampened, reducing neuroinflammation in the aging brain and preserving cognitive function.
To understand why this matters, it helps to appreciate just how consequential the NLRP3 inflammasome has become in the biology of aging. In recent years, researchers have identified chronic, low-grade inflammation, a phenomenon often called inflammaging, as a common thread running through nearly every age-related disease, from atherosclerosis to Alzheimer’s disease. The NLRP3 inflammasome sits near the top of this inflammatory hierarchy. Assembled in response to cellular stress signals, it activates caspase-1, which cleaves precursor forms of inflammatory cytokines into their active versions. In the brain, overactive microglia, the resident immune cells, equipped with hyperactive NLRP3 machinery can transform from vigilant housekeepers into sources of sustained tissue-damaging inflammation.
What makes the new work particularly compelling is the route by which the mushroom compounds reach this intracellular target. Polysaccharides from Ganoderma lucidum are large, complex carbohydrate molecules that, for the most part, cannot cross the blood-brain barrier in any meaningful quantity. For decades, this posed an awkward puzzle for proponents of the mushroom’s neuroprotective reputation: how could a compound that never enters the brain influence brain function? The answer emerging from this and related research is that the polysaccharides act as selective nutrients, or prebiotics, for particular gut microbes. By feeding and expanding Blautia coccoides, they recruit the microbiome as an intermediary, and it is the bacterium’s metabolic output that travels onward to influence the nervous system.
Butyrate is one of the most intensively studied metabolites produced by the human gut microbiota. It serves as the primary energy source for the cells lining the colon, strengthens the intestinal barrier, and, crucially, can cross into systemic circulation and signal to distant organs, including the brain. Among its many documented effects are the inhibition of histone deacetylases, enzymes that regulate gene expression, and the suppression of inflammatory pathways in immune cells. The new study positions butyrate as the critical messenger in the chain connecting the reishi compounds to the aging brain, with Blautia coccoides as the supplier and NLRP3 as the destination.
Blautia coccoides itself is an increasingly prominent character in microbiome science. Belonging to the firm and diverse phylum Firmicutes, this anaerobic bacterium has been associated in various studies with healthy metabolic profiles and anti-inflammatory environments in the gut. Its abundance tends to shift with diet, age, and disease state, and several investigations have linked reduced levels of butyrate-producing bacteria to conditions ranging from inflammatory bowel disease to neurodegenerative disorders. By identifying this species as a key beneficiary of Ganoderma lucidum polysaccharide supplementation, the study provides a concrete, testable link between a traditional medicinal mushroom and the mechanistic vocabulary of modern immunology.
The cognitive consequences reported in the study follow logically from the inflammatory biology. Neuroinflammation is now recognized as a major contributor to age-related impairment of learning and memory. Pro-inflammatory cytokines released by activated microglia interfere with synaptic plasticity, the cellular basis of learning, and can damage neurons over time. By restraining NLRP3 activation and thereby reducing the release of these cytokines, the butyrate-mediated pathway preserves the biochemical environment that synapses need to function. The study’s findings that cognitive measures improved alongside reductions in neuroinflammatory markers support the idea that the behavioral effects were driven by the molecular changes observed.
For the broader field of gut-brain axis research, the study offers a template that others may soon follow. Rather than cataloguing broad correlations between microbiome composition and neurological health, it traces a complete pathway: a defined dietary intervention, a specific bacterial species, a defined metabolite, and a defined molecular target in the host. This level of mechanistic resolution is what the field has been striving toward, because correlations alone cannot distinguish drivers from passengers. If the axis described here holds up in further investigation, it suggests that interventions targeting the microbiome could be engineered with a precision previously reserved for small-molecule drugs.
The clinical implications, while encouraging, warrant careful framing. Aging populations worldwide face rising rates of cognitive impairment and neurodegenerative disease, and current treatment options for preventing or slowing these declines remain limited. Nutritional and prebiotic interventions carry inherent appeal because they are accessible, generally well tolerated, and compatible with long-term use. Ganoderma lucidum polysaccharides, already consumed widely as supplements and functional foods, could in principle be translated into preventive strategies relatively quickly. Yet translation from experimental findings to human therapies requires confirmation in human trials, careful characterization of dosing, and attention to the considerable individual variability of the human microbiome, which can differ dramatically between people and shape how any prebiotic intervention plays out.
There are also deeper scientific questions raised by the work. How durable are the microbiome changes induced by the polysaccharides, and do they persist after supplementation ends? Does the Blautia coccoides-butyrate-NLRP3 axis operate similarly across sexes, genetic backgrounds, and stages of aging? And could enhancing this pathway be relevant not only to normal cognitive aging but to neurodegenerative conditions in which NLRP3-driven inflammation is implicated, including Parkinson’s disease, the journal hosting the publication reflecting a growing interest in these intersections? The study, published on 9 November 2026, arrives at a moment when the scientific community is actively exploring inflammasome inhibitors and microbiome-based therapeutics, and it suggests that ancient remedies and cutting-edge molecular medicine may converge on the same targets.
What the research ultimately underscores is a conceptual shift in how the aging brain might be protected. For decades, efforts to preserve cognition focused almost exclusively on neurons and the molecules acting upon them. The emerging picture is more ecological: the brain’s inflammatory climate is substantially set by actors outside the nervous system, in the bustling ecosystem of the gut, and can be influenced by what that ecosystem is fed. If a polysaccharide from a woody mushroom can tilt that ecosystem toward a bacterium whose metabolic byproducts quiet the inflammasomes of aging microglia, the boundary between nutrition, microbiology, and neurology becomes not just porous but productive. The findings invite a future in which maintaining a sharp mind in old age begins, at least in part, in the gut.
The experimental logic behind the study also highlights why short-chain fatty acids have attracted such attention in aging research. Butyrate concentrations in the gut naturally decline when fiber intake drops or when butyrogenic bacteria are displaced by less beneficial species, a pattern frequently observed in older adults. Restoring this metabolite through a prebiotic strategy differs from delivering butyrate directly, because it recruits the gut’s own microbial machinery to produce the compound locally, where it can act on the epithelium and enter circulation in a physiologically regulated manner. This endogenous route may help avoid some of the tolerability and delivery problems that have complicated direct butyrate supplementation.
The choice of NLRP3 as the downstream target is also notable given the broader pharmaceutical landscape. Several drug developers are pursuing small-molecule NLRP3 inhibitors for inflammatory and neurodegenerative conditions, and the reishi polysaccharide findings suggest that microbiome-based approaches could achieve comparable suppression of the same complex through an entirely different entry point. Whether such dietary modulation can reach the degree of pathway inhibition achieved by synthetic inhibitors remains an open question, but the parallel underscores how convergent different therapeutic traditions can be when aimed at a well-defined molecular node.
It is worth emphasizing that the study’s mechanistic chain was established in experimental models, where microbiome composition, metabolite levels, and inflammasome activation can be measured and manipulated directly. Human aging involves additional layers of complexity, including decades of accumulated dietary history, medication use, and microbial diversity that no animal model fully reproduces. The value of the work lies in supplying a falsifiable hypothesis: that enriching butyrate-producing bacteria should dampen NLRP3 activity and preserve cognition. Testing that hypothesis in well-designed human cohorts, with standardized polysaccharide preparations and longitudinal microbiome monitoring, will determine whether the reishi mushroom’s ancient reputation can be translated into evidence-based practice for protecting the aging brain.
Subject of Research: Ganoderma lucidum polysaccharides ameliorate cognitive decline and neuroinflammation in aging via the Blautia coccoides-butyrate-NLRP3 axis
Article Title: Ganoderma lucidum polysaccharides ameliorate cognitive decline and neuroinflammation in aging via the Blautia coccoides-butyrate-NLRP3 axis
Article References: Zhang, S., Wei, H., Wang, Q., Zhang, M., Wan, G., Wang, J., Leng, J., Li, J., Chen, D., Huang, B., & Ran, J. (2026). Ganoderma lucidum polysaccharides ameliorate cognitive decline and neuroinflammation in aging via the Blautia coccoides-butyrate-NLRP3 axis. npj Parkinson’s Disease. https://doi.org/10.1038/s41531-026-01535-0
Image Credits: AI Generated
DOI: 10.1038/s41531-026-01535-0
Keywords: Ganoderma lucidum, reishi mushroom, polysaccharides, cognitive decline, neuroinflammation, aging, gut-brain axis, Blautia coccoides, butyrate, NLRP3 inflammasome, microbiome, npj Parkinson’s Disease
Cite Scienmag News
APA MLA Chicago
Beatrice Stafford. (September 12, 2026). Reishi Mushroom Compounds Show Promise Against Age-Related Memory Decline in New Study. Scienmag. https://scienmag.com/reishi-mushroom-compounds-show-promise-against-age-related-memory-decline-in-new-study/
Beatrice Stafford. “Reishi Mushroom Compounds Show Promise Against Age-Related Memory Decline in New Study.” Scienmag, 12 September 2026, https://scienmag.com/reishi-mushroom-compounds-show-promise-against-age-related-memory-decline-in-new-study/. Accessed 12 September 2026.
Beatrice Stafford. “Reishi Mushroom Compounds Show Promise Against Age-Related Memory Decline in New Study.” Scienmag. September 12, 2026. https://scienmag.com/reishi-mushroom-compounds-show-promise-against-age-related-memory-decline-in-new-study/
Copy citation Download RIS
Tags: AgingBlautia coccoidesBlautia coccoides and butyrate production in agingbutyratecognitive declinedietary interventions for age-related neurodegenerationGanoderma lucidumGanoderma lucidum compounds and memory preservationgut-brain axisgut-brain axis and neuroinflammationmicrobiomemicrobiome modulation to prevent neurodegenerationneuroinflammationneuroinflammation reduction through gut microbiotaNLRP3 inflammasomeNLRP3 inflammasome inhibition by natural compoundsnpj Parkinson’s Diseasepolysaccharidesreishi mushroomReishi mushroom polysaccharides for age-related cognitive declinerole of short-chain fatty acids in brain healthtraditional East Asian medicine and cognitive aging
